Leucine is animal and plant proteins’ most abundant branched-chain amino acid (BCAA). It is essential in protein synthesis and metabolic function and is sometimes used as a dietary supplement or enhances food flavor (Li et al., 2009). The first BCAAs leucine was discovered by a French scientist from cheese in 1819 named Prust (Wu, 2021). In 1820, Braconnot was the first to use Acid hydrolysis to isolate Leucine from the skeletal muscle and wool. Schulze synthesized Leucine from isovaleraldehyde in 1935 (Karkashadze et al., 2023). It optimized Leucine, an isoleucine isomer essential for optimal growth development. Leucine, isoleucine, and valine, branched-chain amino acids [BCAAs], are essential amino acids that are potent nutritional signaling molecules for regulating protein synthesis that is not synthesized in mammals (McCOY et al., 2009). Leucine has a rich quality of protein foods in BCAAs. The [BCAAs] and the supplement of Leucine wildly used in various clinical situations to maintain muscle mass during weight loss (Zhang et al., 2016). Leucine regulates growth and development through various mechanisms, including protein synthesis, energy metabolism, and immune function. Increasing dietary leucine intake may be an effective strategy for promoting growth and development and maintaining overall health (Zhang et al., 2017). Leucine is an aliphatic isobutyl side chain. That’s ways leucine is classified as hydrophobic white crystalline Amino acid. The molecular formula of Leucine is C6H13NO2. The leucine BCAAs have a 337c melting point, and 5 .8 is an isoelectric point (Gerling et al., 2014). The effect of Leucine in modifying mTOR signaling is not entirely known. Conversely, Leucine promotes protein translation by activating the mechanistic target of the rapamycin complex 1 (mTORC1) pathway. Leucine plays a significant role in stimulating protein synthesis via the mammalian target of rapamycin [mTOR] signaling pathway, fatty acid oxidation, and mitochondrial in both skeletal muscle and adipose tissue (Duan et al., 2016; Li et al., 2011), including placental cells and epithelial cells (Duan et al., 2015). Leucine stimulates mTORC1 activation by bringing the protein to the surface of lysosomes, where growth factors and other amino acids may stimulate it. Multiple downstream targets of mTORC1 are phosphorylated, which stimulates translation initiation and ribosome biogenesis (Liu and Sabatini, 2020). In addition to its role in protein synthesis, leucine also plays a role in the oxidation of fatty acids in skeletal muscle. Leucine stimulates fatty acid oxidation by activating the AMP-activated protein kinase (AMPK) pathway. AMP-activated protein kinase (AMPK) is a cellular energy sensor that controls metabolic rate and energy homeostasis. Leucine prevents lipid buildup in skeletal muscle and increases fatty acid oxidation by activating AMPK (Doi et al., 2005). The mitochondrial function is also affected by leucine. The oxidative phosphorylation process, which produces ATP, occurs in a cell’s mitochondria. Leucine promotes mitochondrial biogenesis, which boosts cellular mitochondrial content and energy production. Leucine promotes mitochondrial biogenesis and function by activating the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1) pathway. Notably, the mTOR pathway significantly impacts the development of mRNA translation and ribosome biogenesis, which need significant amounts of cellular energy (Daher et al., 2022). There is a lot of research on the possible health advantages of leucine supplementation, especially regarding muscle growth, metabolic function, and immunological function. But there are also hazards linked to supplementation, so it is vital to weigh the pros and cons before deciding whether or not to add leucine to your diet (Bauer et al., 2013). There is evidence that leucine may promote muscle protein synthesis and enhance muscle growth in healthy people and those with specific medical diseases like cancer or age-related muscle loss (Ham et al., 2014). One study showed that participants ranged in age from 65 to 82 years old, and the research was a randomized, double-anonymized, placebo-controlled trial of 16 healthy older individuals (8 women and 8 men). Supplementation with leucine or a placebo was given to participants for 6 weeks. Participants took the leucine supplement three times a day, with each dose containing 2.5 g of leucine (Walker et al., 2020). Individuals in the study who took leucine supplements gained significantly more muscle mass than those in the placebo group. Leucine supplementation increased total lean body mass and arm lean mass, but placebo had no effect. The leucine group also saw a significant boost in muscle strength compared to the placebo group, and supplemental leucine may help healthy older people gain muscle and strength (Yoshimura et al., 2019). Further studies are required to evaluate leucine supplementation’s ideal quantities, timing, and long-term effects. One investigation of the long-term effects of leucine supplementation in elderly individuals with sarcopenia. The study’s findings revealed that compared to the control group, the individuals who got the leucine supplement had significantly more muscular mass and strength (Bauer et al., 2015). Physical abilities, including gait speed and stair climbing capability, were improved in the leucine group. Leucine group members also saw a decline in indicators of inflammation, which are often linked to muscle wasting and weakness in older people. So, Research shows that healthy older adults who take supplemental leucine have gains in muscle growth and strength (Liberman et al., 2019). Research on the long-term benefits of leucine supplementation, especially for those with sarcopenia or other muscle-wasting diseases, as well as the ideal dosage, is warranted. Leucine is an important amino acid that must be obtained from food and available from animal- and plant-based sources (Bauer et al., 2015). Some of the finest leucine is an important amino acid that must be supplied via food and may be found in animal- and plant-based sources (Bhat and Karim, 2009). Some of the finest leucine food sources include animal proteins are a source of leucine. Leucine is found in meat, chicken, fish, eggs, and dairy products. For example, three ounces of chicken breast or beef have around 1.5 g of leucine, whereas a cup of milk or yoghurt contains about 0.7 g (Gardner et al., 2019).Proteins from plants Leucine is also found in beans, lentils, peas, soy products, and whole grains. A cup of cooked lentils or soybeans, for example, has around 1.3 g of leucine, while a cup of cooked quinoa contains about 0.9 g. In addition, some food additives and preservatives may also affect the nutritional value of leucine and other amino acids a study found that the addition of sodium nitrite and sodium erythorbate to meat products resulted in a decrease in leucine content. The authors suggest that the reduction in leucine content may be due to the reaction between the preservatives and the amino acids present in the meat (Heaton et al., 2000). This reaction can lead to the formation of nitrosamines, which are known to have carcinogenic effects (Hecht, 1997). Additionally, the reduction in leucine content may have negative effects on muscle protein synthesis, which is important for muscle growth and maintenance (Deutz et al., 2011). Overall, while the current research on leucine is extensive, there are still many areas that need to be addressed in order to fully understand its role in regulating growth and development. Further research into the tissue-specific effects of leucine, its long-term impacts, optimal dosing, and interactions with other nutrients is needed to inform dietary recommendations and improve health outcomes.

The process by which cells create new proteins from amino acids is known as protein synthesis (Argilés et al., 2016). It is essential for developing and maintaining all bodily tissues, including skeletal muscle. Skeletal muscle is very vital for mobility and accounts for a huge portion of the body’s protein turnover. As a result, protein synthesis is critical for sustaining muscle mass and function (Phillips et al., 2009). Protein synthesis in skeletal muscle is a complicated set of metabolic events controlled by many signaling channels. The mTOR pathway, which is stimulated by foods such as amino acids, particularly leucine, is one of the main routes. Leucine stimulates mTOR signaling, which increases muscle protein synthesis and promotes muscular development (Castro et al., 2016). The BCAAs stimulate this procedure by enhancing mTOR pathway components TSC2, Rheb, and Raptor at the onset of mRNA translation (Argueta et al., 2018). The mTOR (mammalian target of rapamycin) pathway regulates protein synthesis and cell proliferation. Upstream signaling molecules that modulate the mTOR pathway include tuberous sclerosis complex 2 (TSC2), a Ras homolog abundant in the brain (Rheb), and the mTOR regulatory-associated protein of mTOR complex 1 (Raptor). TSC2, Rheb, and Raptor are all important regulators of the mTOR pathway, which is a crucial regulator of protein synthesis and cell development. TSC2 inhibits Rheb, which inhibits mTOR activity, while Rheb promotes mTOR to boost protein synthesis. Raptor coordinates the activation and control of mTORC1 to begin protein synthesis in retorting to amino acids (Hong-Brown et al., 2012). The interaction of these molecules regulates the activity of the mTOR pathway, which regulates protein synthesis and cellular development (Hong-Brown et al., 2012). The mechanistic target of rapamycin complex 1 [mTORC1] and mechanistic target of mTOR complex 2 [mTORC2] make up the single MTOR gene in mammals as opposed to the two TOR genes (TOR1 and TOR2) found in yeast (Kim and Guan, 2019). mTOR (mammalian target of rapamycin) is a protein kinase that regulates several physiological functions such as protein synthesis, metabolism, cell growth and proliferation, autophagy, and immunology. mTOR is composed of two distinct complexes, mTORC1 and mTORC2. mTORC1 is the major complex involved in protein synthesis control; it is triggered by a variety of signals, including nutrients, growth hormones such as insulin, and amino acids such as BCAAs (branched-chain amino acids), particularly leucine (Wataya-Kaneda, 2015). mTORC1 regulates protein synthesis by phosphorylating and activating downstream substrates such as S6K (S6 kinase) and 4EBP1/2 (eIF4E-binding protein 1/2), influencing mRNA translation initiation. Rag GTPases are mTORC1 activators; they are part of a nutrient-sensing system that adjusts mTORC1 activity in response to amino acids such as leucine (Chong, 2015). Rag GTPases are defined as a “molecular switch” that activates mTORC1 when amino acids are abundant and deactivates it when they are sparse. mTORC2 has a structure similar to mTORC1, although it is not mainly involved in protein synthesis control. mTORC2 is instead known to regulate the cytoskeleton, differentiation, and cellular metabolism, including glucose and lipid metabolism (Proud, 2019). Both complexes exhibit unique elements and upstream regulators, resulting in downstream signaling variations. Mammalian LST8 [mLST8], proline-rich Akt substrate of 40 kDa [PRAS40], regulatory-associated protein of mTOR [Raptor], regulatory-associated protein of [mTOR], and Dishevelled, EGL-10, and pleckstrin [DEP] domain-containing mTOR make up mTORC1. Raptor is in charge of improving the recruitment of substrates to mTORC1 and is necessary for mTORC1’s localization to the lysosomal membrane (Maiese et al., 2013). mTORC2 contains components that are distinct from mTORC1, such as Raptor-independent companion of mTOR [Rictor] and mammalian stress-activated protein kinase interacting protein [mSin1], as well as shared components like mLST8 and DEPTOR (Awasthi et al., 2016).

While PRAS40 improves both mTORC1 and mTORC2 functions, DEPTOR suppresses both complexes. A more detailed examination of the structure and composition of mTOR complexes can be found elsewhere (Wiza et al., 2012). mTOR signaling was studied in the development of breast cancer and resistance to targeted therapy (Figure 1). The research discovered that mTOR signaling hyperactivation is linked to the development of breast cancer and resistance to targeted therapy (Dong et al., 2021). The researchers used mathematical modeling to investigate the signaling networks that govern mTOR hyperactivation in breast cancer cells. They discovered that oncogenic protein kinase C (PKC) activation plays a crucial role in the hyperactivation of mTOR signaling in breast cancer cells. PKC is an enzyme that controls cell growth, differentiation, and survival (Fyffe and Falasca, 2013) PKC overexpression has been linked to various malignancies, including breast cancer. Furthermore, scientists discovered that inhibiting PKC signaling lowered mTOR activity and cell growth and proliferation (Tee et al., 2003). The researchers also looked at the significance of mTOR signaling in breast cancer cell resistance to targeted therapy (O’Brien et al., 2014). They discovered that cancer cells resistant to targeted medicines like trastuzumab had greater levels of mTOR signaling activity than cells responsive to targeted therapies (Gajria and Chandarlapaty, 2011). In one of the studies, the researchers discovered that leucine supplementation boosted the phosphorylation of downstream targets of the mTOR pathway, such as ribosomal protein S6 and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) in the in vitro section of the study. Protein synthesis genes such as eukaryotic elongation factor 2 and ribosomal protein S6 were upregulated in response to leucine supplementation in C2C12 myotubes (Salles et al., 2013). In this study, the researchers separated the male Sprague-Dawley rats into two groups: a control group and a leucine-supplemented group. The leucine-supplemented group received 2.25 g/kg body weight per day of leucine for 10 days (Zanchi et al., 2012). The phosphorylation levels of mTOR and downstream targets and protein production were assessed in rat skeletal muscle. The findings demonstrated that leucine supplementation increased the phosphorylation of mTOR and its downstream targets, including p70S6K and 4E-BP1, in the rats’ skeletal muscles. Increased phosphorylation was followed by increased protein synthesis in the rats’ skeletal muscles. The researchers also discovered that supplementing with leucine caused muscular hypertrophy, as indicated by an increase in cross-sectional area and muscle fiber diameter (Biolo et al., 1995). According to the findings, leucine supplementation increases the mTOR signaling system, resulting in increased protein synthesis and, as a result, muscular growth. The researchers hypothesized that leucine supplementation enhances amino acid availability in skeletal muscle, activating the mTOR signaling pathway. The study of Laplante and Sabatini provides a comprehensive description of how mTOR signaling regulates protein translation, metabolism, cell growth, proliferation, and survival by integrating external and intracellular inputs (Ben-Sahra and Manning, 2017). Tumor development, angiogenesis, insulin resistance, adipogenesis, and T-cell activation are all biological activities activating mTOR due to their high energy and food demands (Ananieva et al., 2016; Carbone et al., 2012). Mammalian Rag GTPases A-D may combine into heterodimers. Rag A and Rag B are a heterodimer that interacts with mTORC1 [via Raptor] and is activated by the amino acid leucine, which promotes Rag A’s and Rag B’s GTP loading (Sancak et al., 2008). For Leucine to perform its regulatory role, it must be ligated to its transfer RNA, which is catalyzed by the enzyme leucyl-transfer RNA synthetase (Wang X. et al., 2021). This enzyme responds to cellular levels of Leucine by stimulating the Rag complex. After being activated by Rag GTPase, mTORC1 is triggered to go to the surface of lysosomes (Bhat and Karim, 2009). That’s where mTORC1 activates itself by binding to another protein, the small GTPase Ras homolog abundant in the brain [Rheb] (Jewell et al., 2015). The lysosome plays a crucial role in amino acid sensing by the mTORC1 signaling pathway. The interaction between mTORC1, Rag GTPases, and Rheb on the lysosomal surface requires the presence of amino acids like Leucine (Greenwell et al., 2017). Moreover, a leucine-supplemented diet has enhanced IGF-1 and IGF-2 gene and protein expression in the fetal liver, potentially alleviating fetal growth constraints. One recent research shows that overexpression of Leucine in SLC6A14 increased blastocyst activation. mTOR is a key player in blastocyst development (González et al., 2012). The study shows that Leucine is important in regulating the mTORC1 signaling pathway in various cellular functions. Recent research has identified additional roles for leucine in various other physiological processes, including adipocyte differentiation, lipid metabolism, and bone metabolism (Ra and Dm, 2017). The mechanisms leucine regulates these processes are complex and involve multiple signaling pathways. Overall, the current research suggests that leucine supplementation may have therapeutic potential in treating various metabolic and musculoskeletal disorders. Furthermore, protein synthesis is necessary for general health and wellbeing. Proteins have several roles in the body, including the synthesis of enzymes, hormones, and neurotransmitters. They also give structural support to cells and tissues, aid in chemical movement throughout the body, and play a significant role in immunological function.

Since 1999, the pioneer in leucine functional research has investigated Leucine’s impact on muscle protein synthesis and its mechanisms (Hecht, 1997). First, his team demonstrated that Leucine increases human muscle protein synthesis and recovery after exercise despite increasing plasma insulin levels (Anthony et al., 2000; Zhang et al., 2017). The mammalian target of rapamycin (mTOR) is a protein kinase, an enzyme that regulates cellular activities such as cell development, proliferation, and metabolism. mTOR is a key component of the signaling system that regulates muscle protein synthesis in response to leucine and other amino acids (Hall, 2008). These proteins are regulated by mTOR kinase activity and are called downstream target proteins. p70 ribosomal S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) are two of the most important downstream target proteins of mTOR in skeletal muscle protein synthesis. The eukaryotic cell’s first growth factor, Protein 4E-binding protein 1 (4E-BP1), binds to the essential eukaryotic initiation factor 4E (eIF4E) and blocks its ability to initiate protein translation (Argilés et al., 2016). When leucine and other amino acids activate mTOR kinase, it phosphorylates 4E-BP1, causing it to relieve inhibition on eIF4E. This release enables the eIF4F complex to assemble, which is required for mRNA translation to start. P70 ribosomal S6 kinase 1 (S6K1) is a protein kinase that phosphorylates ribosomal protein S6 in response to leucine and other amino acid stimulation of mTOR. Ribosomal protein S6 is required for the translation of mRNA into new proteins. For this procedure to be effective, S6 must be phosphorylated by S6K1 (Deng et al., 2014). After many experimental results showed that Leucine stimulates muscle protein synthesis in pigs, rats, and humans (Crozier et al., 2005). One study found that for 4 weeks, the researchers gave male rats a diet containing varying doses of leucine. Leucine amounts evaluated were 3%, 4.5%, and 6% of total dietary protein, respectively (Li et al., 2013). The study revealed that increasing leucine consumption was linked to a dose-dependent increase in muscle protein synthesis rates (Robinson et al., 2013). The researchers discovered that rats with a diet containing 6% leucine had the best muscle protein synthesis rates. Furthermore, muscle protein synthesis rates rose by nearly 20% in rats with a 4.5% leucine diet compared to those with a 3% leucine diet (Norton et al., 2009). The authors hypothesized that the rise in muscle protein synthesis rates seen with increased leucine consumption was caused by the activation of muscle protein synthesis signaling pathways. Leucine, in particular, stimulates the mTOR signaling pathway, which is important in controlling muscle protein synthesis. Furthermore, according to the researchers, leucine enhanced the phosphorylation of the eukaryotic initiation factor 4E binding protein-1 (4E-BP1), which is involved in controlling protein translation initiation. This data implies that leucine may also improve protein translation efficiency, increasing muscle protein synthesis rates (Norton et al., 2009). Overall, the findings imply that increasing dietary leucine consumption may improve muscle protein synthesis rates in rats, likely via activation of the mTOR signaling pathway and higher protein translation efficiency (Li et al., 2013). Another study, especially in neonates, discovered that supplementing Leucine or its metabolites alpha-ketoisocaproic acid and B-hydroxy—methyl butyrate significantly increases newborn muscle protein synthesis (Wheatley et al., 2014). Protein synthesis regulators PHAS-I and p70 S6 kinase are upregulated in pancreatic -cells in response to leucine supplementation in a protein-deficient diet. These cells are responsible for protein translation and mitogenic signaling (Peng et al., 2012). Here are some studies in the table related to leucine help in growth development and protein synthesis.

Table 1 shows that leucine helps in muscle growth in different Animal models.

Leucine has been shown to increase MPS and even certain other physiological processes. This approach entails collecting a muscle biopsy from a patient before and after leucine administration, then analyzing the tissue’s protein level to determine leucine’s impact on MPS and other physiological processes. The findings will reveal whether or not MPS rises after taking leucine. The authors suggest Leucine may be critical for variable insulin secretion and glucose homeostasis (Yang et al., 2010). Leucine is more effective than other necessary amino acids in boosting MPS via activating mTORC1 (Le Plénier et al., 2012). Leucine also reduces muscle proteolysis when paired with exercise, resulting in a synergistic MPS response. Activation of mTORC1 and the operation of its “coincidence detector,” both controlled by small GTPases, are, thus, essential for protein synthesis in skeletal muscle (Reiners et al., 2022). One study examined the effects of leucine supplementation on lactating dairy cows. For 4 weeks, eight multiparous Holstein cows were fed a regular diet and supplemented with 100 g/day of leucine (the treatment group) or an equal amount of a placebo supplement (control group) (Schilde et al., 2021). The study’s findings revealed that cows in the leucine supplementation group produced considerably more milk than those in the control group, with an average increase of 2.2 kg, or 7.6%, more milk produced daily. Furthermore, the leucine supplementation group had considerably greater milk protein output and enhanced nitrogen use efficiency, indicating increased protein synthesis in the mammary gland (Yoder et al., 2020). Furthermore, the Leucine supplementation group had higher levels of growth hormone, insulin-like growth factor-I (IGF-I), and key signaling proteins such as mTOR and phosphorylated ribosomal protein S6, all of which are involved in normal mammary gland development and protein synthesis (Sobolewska et al., 2009). Another study discovered that supplementing with leucine might promote mammary gland growth and boost milk supply and composition in dairy cows. The study utilized 16 nursing Holstein cows randomly allocated to either a control or a treatment group and fed a diet supplemented with 60 g of leucine per day for 12 weeks. So cows in the leucine treatment group produced considerably more milk protein, fat, and lactose than the control group, with an average of 12.5% more milk produced daily (Gao et al., 2015). The study’s results suggest that supplementing the diet of nursing Holstein cows with Leucine can increase milk production and quality. Furthermore, the leucine supplementation group showed higher growth hormone, IGF-I, and mTOR signaling proteins in the mammary gland, indicating that protein synthesis and development were promoted (Gao et al., 2015). Leucine may have comparable impacts on other animal metabolic processes, including protein synthesis and muscle growth and development. Leucine supplementation may benefit animals with muscle-wasting disorders or people with sarcopenia, categorized by a loss of muscle mass and function. Furthermore, leucine supplementation may have used in sports nutrition as a dietary supplement for athletes wanting to increase muscle growth and improve performance (Holeček, 2017). The capacity of leucine to enhance muscle protein synthesis and growth offers athletes a viable technique for increasing lean muscle mass while decreasing recovery time after exercise. Similarly, a study found that leucine supplementation improved milk production and composition in lactating dairy cows by stimulating protein synthesis and mammary gland development (Li et al., 2011). Leucine has been shown to regulate animal growth and development through other mechanisms in addition to its effects on mTOR signaling. Supplementing with Leucine, for example, has increased the expression of genes in skeletal muscle, liver, and adipose tissue involved in energy and lipid metabolism (Surh et al., 2005). The studies looking into how leucine supplementation affects gene expression in fatty tissue, liver, and skeletal muscle. Male Wistar rats were given a diet with either 2% leucine or 1% leucine (the control group) for a period of 4 weeks (Donato et al., 2006). Supplementing with leucine significantly increased the expression of genes involved in energy and lipid metabolism in skeletal muscle, liver, and adipose tissue, as shown by the results of the research. The leucine supplementation group showed increased expression of genes involved in fatty acid oxidation, including carnitine palmitoyl transferase 1 (CPT1) and acyl-CoA oxidase (ACO), and genes involved in glucose metabolism, including glucokinase (GK) and glucose transporter 4 (GLUT4) (Donato et al., 2007). Leucine-supplemented rats showed greater amounts of transcription factors that regulate energy and lipid metabolism, such as peroxisome proliferator-activated receptor (PPAR) and insulin receptor substrate 1 (IRS1) (Eller et al., 2013). These alterations in gene expression were associated with higher insulin sensitivity and lower blood glucose and cholesterol levels, suggesting that leucine supplementation enhanced metabolic health (Yoon, 2016). Another study discovered the impact of leucine supplementation on gene expression in dairy goat liver and skeletal muscle. For 12 weeks, the goats were fed a diet enriched with either 0 or 0.80% leucine (Strable and Ntambi, 2010). So, the result in the liver and skeletal muscle, leucine supplementation increased the expression of genes involved in lipid metabolism, such as PPAR, acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS), as well as genes involved in glucose metabolism, such as glycogen synthase (GYS) and glucose transporter 1 (GLUT1). The goats given leucine also exhibited superior lipid profiles, increased glycogen stores in the liver, and enhanced insulin sensitivity (Zhao et al., 2020). Furthermore, Leucine administration boosted the expression of glucose metabolism genes such as glycogen synthase (GYS) and glucose transporter 1 (GLUT1) in the goats’ liver and skeletal muscle. These findings imply that Leucine supplementation may enhance glucose and lipid metabolism in dairy goats, perhaps leading to improved metabolic health and milk output. Leucine may also have anti-inflammatory and antioxidant effects that promote animal health and growth (Jansson et al., 2012). How adding leucine to a diet helps mice with NAFLD by altering their gene expression. When fat builds up in the liver without alcohol, a condition known as nonalcoholic fatty liver disease (Gao et al., 2019), the researchers utilized mice fed a high-fat diet to generate NAFLD. The mice were then separated into two groups, one getting leucine supplementation (at a dosage of 0.68% leucine) and the other serving as a control group with no supplementation. The research lasted 8 weeks (Kim B. et al., 2017). The study’s findings revealed that leucine supplementation dramatically boosted the expression of genes involved in lipid metabolism in the livers of NAFLD mice. Leucine-supplemented mice showed higher levels of expression of PPAR and acyl-CoA oxidase (ACO), both of which are involved in the oxidation of fatty acids in the liver (Landon et al., 2020). In a separate experiment, researchers examined how leucine supplementation affected gene expression in the skeletal muscle of diabetic rats. The rats were given a high-fat diet with either no added leucine (control group) or 0.5% leucine (test group) for 8 weeks. Leucine supplementation significantly increased the expression of genes involved in glucose and lipid metabolism in skeletal muscle, including GLUT4, peroxisome proliferator-activated receptor (PPAR), and lipoprotein lipase (LPL). Leucine supplementation improved glucose tolerance, insulin sensitivity, and muscle structure in diabetic rats. These results suggest that leucine supplementation may prevent and cure type 2 diabetes by increasing insulin sensitivity and regulating gene expression in glucose and lipid metabolism (Zhang et al., 2007). The above studies show that leucine supplementation can boost the expression of genes complicated in energy and fat metabolism in a variety of tissues. This shows that leucine might be useful in treating metabolic illnesses such as diabetes, obesity, and fatty liver disease, which are characterized by dysregulation of energy and lipid metabolism. Generally, this study provides evidence that Leucine activates the mTORC1 pathway through a complex molecular mechanism involving the translocation of mTOR to the lysosomal surface and the activation of downstream effectors. Leucine’s activation of the mTORC1 pathway is a crucial mechanism by which Leucine promotes protein synthesis and muscle growth.

The capacity of leucine to activate the mechanistic target of the rapamycin (mTOR) signaling pathway, which plays a key role in controlling protein synthesis and cell proliferation, is well established. (Kimball and Jefferson, 2006). Recent research has given insight into the intricate processes involved in the leucine sensing system, which underpins mTOR activation. Sestrin2, CASTOR1, and leucyl-tRNA synthetase (LRS) are the three primary components of the leucine sensing system (Sekine et al., 2021). Here’s some background on each component and its involvement in the leucine sensing system (Schuler et al., 2021). Sestrin2 is a stress-responsive protein that is essential for the leucine sensing system. Sestrin2 has been reported to interact with many proteins in the pathway, including GATOR1 and GATOR2, which control the activities of mTORC1 via the Rag GTPases. Sestrin2 can activate mTORC1 indirectly by blocking GATOR2 or activating GATOR1, enabling Rag GTPases to activate mTORC1 (Ho et al., 2016). CASTOR1, a cytosolic protein, was recently shown to be an arginine sensor. CASTOR1 interacts with Sestrin2, which is required for mTORC1 activation in response to leucine. CASTOR1 can bind to leucine and inhibit GATOR2, activating mTORC1. LRS (leucyl-tRNA synthetase) is an enzyme that charges tRNA molecules with leucine (Chantranupong et al., 2016). According to recent research, LRS is also implicated in the leucine sensing system. LRS can interact with GATOR2 and decrease its function, resulting in mTORC1 activation. These three components collaborate to activate mTORC1 in response to leucine levels. The precise methods of interacting with and regulating one another are still being discovered (Liu and Sabatini, 2020). Understanding these pathways might greatly impact the development of novel medications and treatments for illnesses including cancer, metabolic disorders, and muscle wasting caused by mTOR signaling failure (Kim JH. et al., 2017). Activation of mTOR by leucine results in the stimulation of protein synthesis and the inhibition of protein degradation, leading to an overall increase in muscle mass (Norton and Layman, 2006). The insulin signaling system, which controls glucose metabolism and energy balance, is activated by Leucine in addition to the mTOR pathway. They used a mouse model to examine the effect of leucine on protein metabolism. They specifically looked at the effects of a low-protein diet on muscle mass and protein synthesis, as well as the ability of leucine supplementation to reverse these effects (Crozier et al., 2005). The mice were separated into four groups and fed various diets: a regular protein diet (20% protein), a low protein diet (5% protein), and a low protein diet supplemented with either 2% or 4% leucine. After 21 days, the researchers examined muscle mass, protein synthesis rates, and other protein metabolism markers (Zhang et al., 2007). The results revealed that mice fed a reduced protein diet had considerably less muscle mass than mice fed a regular protein diet. On the other hand, Mice fed a low-protein diet supplemented with leucine had more muscle mass than mice on a low-protein diet alone (Anthony et al., 2000). Furthermore, leucine supplementation enhanced protein synthesis rates in these mice’s muscles, demonstrating that leucine can have an anabolic impact on protein-restricted diets. By translocating glucose transporter type 4 (GLUT4) to the cell membrane, leucine-mediated activation of the AMPK pathway promotes glucose uptake in peripheral tissues, notably skeletal muscle. This mechanism promotes glucose absorption by cells and activates glycolysis and glucose oxidation for energy production (Farooqui, 2013). Enhancing both insulin secretion and glucose uptake and utilization by peripheral tissues, which regulates energy balance by promoting energy expenditure and inhibiting energy storage (Rieu et al., 2004). In one study, modest dosages of Leucine supplementation increased fat loss and efficiently boosted muscle protein synthesis in food-restricted rats (Rieu et al., 2004). Myofibrillar muscle protein synthesis in males can be stimulated by a low-protein (6.25 g) mixed macronutrient beverage including a high-protein (5 g total Leu) dosage (Churchward-Venne et al., 2014). In 1989 researchers looked at how men and women’s paths diverged. Fasting plasma amino acid levels were measured in 22 young men (aged 25–35), 21 older men (aged 65–85), 23 men (aged 65–92) with dementia who were fed orally in an institution, and 17 men (aged 65–88) who were fed artificially (Rudman et al., 1989). BCAA levels were highest in the first group, dropping in the third and fourth. In another research, 72 healthy volunteers aged 23 to 92 were split into six groups of 12 based on sex and age (41–42, 43–44, and >60 years). Men had higher amounts of essential and branched-chain amino acids (BCAAs) than women; total amino acid, EAA, and non-essential amino acid levels decreased with age (Clemmesen et al., 2000). A recent Korean study in adults aged 50–64 investigated the link between amino acid intake and skeletal muscle mass index (SMI). Leucine, isoleucine, and valine intake [measured by a 24-h recall] were all within the reference range for the Korean population, and there was a statistically significant positive correlation between BCAA intake [in g/day] with food and the SMI (Kang et al., 2020). The results of the aforementioned research indicate that supplementing with a leucine-rich protein may have positive benefits by halting muscle loss, especially among middle-aged men and women. Skeletal muscle recovery after exercise is also facilitated through leucine supplementation (Draganidis et al., 2017). So, you see the above data in different studies shows that BCAAs, especially Leucine, are essential for protein synthesis and growth development. Still, the actual age/Gram in the diet is required for further study.

The leucine zipper motif, which comprises a heptad repeating sequence of leucine residues, creates a protein dimerization domain that allows transcription factors to bind to DNA. Once bound, these factors may activate or repress gene expression by recruiting co-activators or co-repressors to the regulatory domains of target genes, respectively (Landschulz et al., 1988). This process is required for cellular differentiation, development, response to external stimuli, and preservation of cell homeostasis. The leucine zipper is a structural motif found in some transcription factors, which are proteins that regulate gene expression (Nijhawan et al., 2008). Within transcription factors, the leucine zipper motif generates an alpha-helical structure with a repeating heptad sequence of leucine residues that protrude from one face of the helix (Ogata et al., 1992). In every seventh position along the alpha helix, leucine residues face inward towards the helix center. When two transcription factors with leucine zipper motifs engage, their helices align, and the leucine residues of each factor interact in a complementary manner (Ellenberger et al., 1992). This contact between the two helices’ leucine residues is known as a “leucine zipper,” which creates a stable dimerization domain between the two transcription factors (Fang et al., 2018). The leucine zipper motif is a dimerization domain that allows two identical or similar proteins to bind together and form a functional transcription factor complex. One example of a gene regulated by a leucine zipper transcription factor is the c-fos proto-oncogene (Chang et al., 1990). One study discovered the significance of GCNF (Germ Cell Nuclear Factor), a nuclear hormone receptor superfamily member, in controlling gene expression throughout embryonic development. The researchers wanted to figure out how GCNF works in the transcriptional regulation of genes that affect cellular differentiation and development. The rest of the transcription factor can bind to particular DNA sequences and influence gene expression after the dimerization domain is established. The dimerization domain is required for transcription factor binding to DNA because it connects two DNA-binding domains, allowing them to interact collaboratively and with great specificity (Rajković et al., 2010). The researchers investigated the function of GCNF using a mix of genetic and molecular biology methods. They compared transgenic mouse models producing a shortened version of GCNF without repressor activity to wild-type mice (Kavarthapu and Dufau, 2015). They also employed chromatin immunoprecipitation (ChIP) tests to identify GCNF genomic targets and study how they affect gene expression. The research showed that GCNF acts as a transcriptional regulator, suppressing the expression of Hox genes and pluripotency maintenance genes like Nanog and Oct4 (Hay et al., 2004). The researchers discovered that GCNF binds to regulatory areas of these target genes, attracting co-repressors and promoting chromatin remodeling, which results in gene expression suppression. Furthermore, the study indicated that GCNF plays an important role in maintaining the balance between pluripotent and differentiated cell states. For differentiation to begin, GCNF-mediated suppression of pluripotency genes is required (Ding et al., 2015). The researchers discovered that GCNF is downregulated throughout lineage determination, indicating that GCNF-mediated suppression of pluripotency genes is only required early in differentiation (Gu et al., 2005). Overall, the work clarified the mechanism of action of GCNF in the transcriptional control of genes involved in cellular differentiation and development. The research discovered that GCNF operates as a transcriptional repressor, controlling the balance of cells’ pluripotent and differentiated states. It has important implications for understanding embryonic development and finding possible targets for therapeutic approaches in disorders requiring abnormal gene expression regulation. This gene regulates cell growth and differentiation, and various extracellular signals, including growth factors and cellular stress, induce its expression. The leucine zipper transcription factor that regulates c-fos is called Fos, and it forms a heterodimer with another transcription factor called Jun to activate the c-fos promoter (Ahn et al., 1998). Several studies have investigated the role of leucine zipper transcription factors in gene regulation. For example, a study of the function of a leucine zipper transcription factor called GCN4 in yeast. The authors found that GCN4 regulates the gene expression in amino acid metabolism and that changes in its availability modulate its activity (Harding et al., 2000). Another study investigated the function of a leucine zipper transcription factor called AtbZIP11 in Arabidopsis thaliana. According to one study, abscisic acid (ABA), a plant hormone critical in response to diverse environmental stresses, induces AtbZIP11 (Yoshida et al., 2010). The scientists discovered that the expression of AtbZIP11 was increased in Arabidopsis plants treated with drought and high-salinity stress, confirming its significance in the abiotic stress response (Yoshida et al., 2014). Further, to study the role of AtbZIP11 in stress response, the researchers created transgenic Arabidopsis plants with both AtbZIP11 overexpression and AtbZIP11 under expression. The scientists discovered that AtbZIP11 modulates the expression of numerous genes involved in ABA production and signaling, osmotic stress response, and reactive oxygen species scavenging by studying the expression patterns of genes involved in abiotic stress response in both transgenic plants (Floris et al., 2009). Leucine zipper transcription factors (TFs) are useful in biotechnology they may be utilized to tailor cell behavior. Cancer cells’ proliferation can be slowed, for instance, by manipulating their gene expression levels. The researchers started by looking at ATF3 expression levels in breast cancer cell lines with different metastatic potentials. They discovered that highly metastatic breast cancer cells had much lower levels of ATF3 expression than less metastatic cells, indicating that ATF3 may play a role in limiting breast cancer cell metastasis. (Wang H. et al., 2021). To test this notion, the scientists used siRNA targeting ATF3 in lowly metastatic breast cancer cells to undertake knockdown tests. They discovered that ATF3 deficiency boosted cell motility, invasion, and metastasis both in vitro and in vivo (Xie et al., 2021). On the other hand, overexpression of ATF3 in highly metastatic breast cancer cells reduced metastasis in vivo, So these findings imply that ATF3 acts as a tumor suppressor in breast cancer by preventing cancer cell spread (Kwok et al., 2009). The researchers next looked at the molecular processes that underpin ATF3’s function in breast cancer metastasis. They discovered that ATF3 increases the expression of the MET tyrosine kinase, which is known to control cell motility and invasion. They also discovered that in breast cancer cell lines and clinical samples, MET expression was adversely linked with ATF3 expression (Shi et al., 2018). Furthermore, they demonstrated that MET overexpression could reverse the metastatic phenotype caused by ATF3 knockdown. Finally, the authors suggested that modulating ATF3 expression or its downstream targets, such as MET, might be a potential therapeutic method for breast cancer therapy, especially in patients with severe metastatic illness (El-Tanani et al., 2022). Overall, this study sheds light on the function of ATF3 in breast cancer metastasis and lays the groundwork for future research into the therapeutic targeting of ATF3 or its downstream targets for breast cancer therapy. Gene expression regulation is important for many animals and biological processes, and leucine zipper transcription factors are a big part of this. As more research is done, scientists will learn more about how these proteins work and how they could be used in biotechnology and medicine.

Multiple studies conducted in the 1970s showed that immune function was impaired in those who did not consume enough Leucine or other BCAAs. (Cynober and Harris, 2006). Leucine is an essential amino acid that plays a crucial role in many physiological processes in the human body, including protein synthesis, muscle growth, and immune function. In particular, Leucine has been revealed to play a critical role in initiating and regulating immune responses (Marc Rhoads and Wu, 2009) and activates the mammalian target of the rapamycin [mTOR] signaling pathway, which regulates cell growth, metabolism, and immune function. mTOR signaling is required for immune cell development and function, including T, B, and natural killer [NK] cells (O’Brien and Finlay, 2019). The supplementation of Leucine has been shown to increase the production of perforin and granzyme B, two key molecules that NK cells use to destroy infected or cancerous cells (Bratke et al., 2005). Leucine also plays an essential role in controlling the synthesis and operation of antibodies, B-cell-produced proteins crucial for defending the body against infections. Leucine has been demonstrated to increase the production of immunoglobulin A [IgA], an antibody essential for defending the body’s mucous membranes (Terezhalmy et al., 1996). Human peripheral blood mononuclear cells [PBMCs] and sheep splenocytes [Spleen cells] were used to examine the immunomodulatory effects of leucine metabolites [HMB, KIC] (Cruzat et al., 2018). Studies have shown that leucine supplementation can enhance immune function in various ways. For example, it can increase the production of T cells, important immune cells that help fight infections. The effects of leucine supplementation on immunological function in mice should be investigated. They were particularly interested in the effect of leucine on T-cell generation and activation, both of which are important components of the immune system. The researchers fed mice a leucine-supplemented meal while a control group was offered a conventional diet without supplementation. T-cell abundance and activation in the mice were then examined. The researchers discovered that giving mice leucine enhanced the number of T cells, namely, CD8⁺ and CD4⁺ T cells (Song et al., 2020). These T cells were then evaluated to see if they could develop into effector cells, which are crucial in combating infections (Song et al., 2020). According to the findings, leucine supplementation increased T-cell development into effector cells, indicating an improved ability to protect against infections. Furthermore, the researchers discovered that leucine supplementation increased T-cell proliferation, allowing for a faster and more effective response to infections (Bermon et al., 2017). According to the study, Leucine was also shown to enhance the production of cytokines, which are essential signaling molecules that govern immunological responses. To clarify, the researchers discovered that leucine supplementation improved T-cell proliferation and differentiation and their ability to create cytokines, which are essential signaling molecules that govern immune responses (Yoon et al., 2018). The researchers discovered that leucine supplementation increased the synthesis of interferon-gamma (IFN-), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-), all of which are cytokines linked with improved immune function and infection protection (Li et al., 2018). Overall, the findings imply that supplementing with leucine can improve immune function in mice by enhancing T-cell generation, differentiation, and activation. The study found that the mechanism of leucine-induced immunological enhancement includes the activation of cellular signaling pathways that control T-cell proliferation and differentiation. Furthermore, leucine has been shown to have anti-inflammatory properties, which can help to reduce inflammation in the body and support immune function. Inflammation is a natural response to infection and injury, but chronic inflammation can impair immune function and increase the risk of disease (Eddleston et al., 2007). Leucine plays a critical role in maintaining immune function, and its supplementation may have therapeutic potential for improving immune health. However, it is essential to consult a healthcare professional before starting any new supplements or dietary changes.

Leucine has been studied extensively because of its function as a nutritional signal activating the mTORC1 pathway in various functions, including muscle function, insulin resistance, and immune response activation. In addition to being critical for muscular growth, getting enough leucine is important for your health and wellbeing in general. It aids in the upkeep of strong bones, controls blood sugar, and promotes a robust immune system. Inadequate leucine intake has been linked to various health issues that may reduce quality of life. To maintain a healthy and robust body, consuming sufficient amounts of leucine-rich meals or supplements is essential. Putting effort into your health now will pay you in the long run. Leucine is essential for nutrition and physiological activities such as metabolism of carbohydrates and fats, protein synthesis, digestive tract wellness, and immune system performance. The potential effect of leucine is brief below (Figure 4).

The potential therapeutic effects of leucine supplementation have been examined in a various scenario, as a dietary supplement for the treatment of obesity and type 2 diabetes, due to leucine’s ability to affect a variety of physiological processes through mTOR and perhaps other signaling pathways. Leucine is an essential amino acid that regulates protein synthesis and cellular metabolism. Lysosomes can detect high leucine levels and generate an anabolic response, increasing protein synthesis and cell development. However, when leucine levels are low, lysosomal activity may be inhibited, favoring catabolism and energy conservation. Although the precise mechanisms governing lysosomal leucine sensing remain unknown, new investigations have identified many signaling pathways and molecular sensors, including mTOR and the Rag GTPases. Overall, the involvement of lysosomes in leucine sensing shows the complicated interplay between nutrition availability and cellular metabolism, which could have significant implications for developing innovative therapeutics for metabolic disorders and aging-related diseases.

The possibility that leucine is one of the “active components” in high-protein diets has prompted interest in studying its potential medicinal uses. Many studies have shown that eating a diet rich in protein may help reduce weight and regulate blood sugar. Research has shown that increasing dietary leucine intake can improve glucose tolerance, reduce insulin resistance, and promote weight loss, particularly in individuals with obesity or type 2 diabetes. These effects appear to be due to leucine’s ability to stimulate thermogenesis, increase fatty acid oxidation, and improve insulin signaling, which can promote healthy glucose metabolism and weight loss. Based on the data presented, leucine supplements are not expected to be useful in treating obesity. Finally, the therapeutic potential of leucine for enhancing glucose homeostasis was investigated. However, the mechanisms by which leucine supplementation improves glucose tolerance remain unclear and may be somewhat dependent on weight loss. It is worth noting that studying the molecular mechanisms of leucine action in whole animals (in vivo) proves challenging due to its complexity. Consequently, researchers use cell culture methods (in vitro) as a valuable approach to unravel the intricate mechanisms underlying leucine action. Nevertheless, it is important to acknowledge certain limitations associated with the use of cell culture systems. In vitro systems rely on immortal cell lines that differ from normal cells, which necessitates the validation of in vitro findings through in vivo methods. Future prospective studies on the role and mechanism of leucine in regulating animal growth and development through mTOR have the potential to make significant contributions to animal health, welfare, and production, as well as to our understanding of the fundamental mechanisms underlying muscle growth and tissue repair in animals.